Elisabeth M G de Vries1, Junfeng Wang2, Mariska M G Leeflang2, Kirsten Boonstra1, Rinse K Weersma3, Ulrich H Beuers1, Ronald B Geskus2, Cyriel Y Ponsioen1. 1. Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. 2. Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. 3. Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, the Netherlands.
Abstract
BACKGROUND: Primary sclerosing cholangitis (PSC) is a slowly progressive liver disease. Reliable biomarkers to predict outcome are urgently needed to serve as surrogate endpoints and/or stratifiers in clinical trials. Reduction in serum alkaline phosphatase (ALP) has been proposed as prognostic surrogate marker in PSC. The aim of this study was to asses if ALP at diagnosis (T0), 1 year later (T1), and percentage change between both time points hold prognostic value, and to determine the optimal threshold. METHODS: We retrospectively collected ALP levels at T0 and T1 for patients included in a large PSC cohort. The association of ALP at T0, T1, and percentage change with the combined endpoint (PSC-related death, liver transplantation) was analysed. Predictive value was determined using C-statistics. RESULTS: A total of 366 patients were included, of whom 66 (18%) reached an endpoint: 26 (7%) PSC-related death, 40 (11%) liver transplantation. At T0 and T1, 84% used ursodeoxycholic acid. A positive association was observed between level of ALP at T0 and T1 and the hazard of reaching an endpoint, up to values around 2.5 times upper limit of normal (xULN). A larger decrease in ALP between T0 and T1 decreased the event rate. A range of thresholds (0.5-3×ULN) with about similar C-statistics was found. In this cohort, the optimal threshold was 1.3×ULN at T1. CONCLUSION: ALP can be used to discriminate between PSC patients with a good and a poor prognosis. These findings indicate that ALP can serve as stratifier, and potentially as surrogate endpoint for clinical trials in PSC.
BACKGROUND:Primary sclerosing cholangitis (PSC) is a slowly progressive liver disease. Reliable biomarkers to predict outcome are urgently needed to serve as surrogate endpoints and/or stratifiers in clinical trials. Reduction in serum alkaline phosphatase (ALP) has been proposed as prognostic surrogate marker in PSC. The aim of this study was to asses if ALP at diagnosis (T0), 1 year later (T1), and percentage change between both time points hold prognostic value, and to determine the optimal threshold. METHODS: We retrospectively collected ALP levels at T0 and T1 for patients included in a large PSC cohort. The association of ALP at T0, T1, and percentage change with the combined endpoint (PSC-related death, liver transplantation) was analysed. Predictive value was determined using C-statistics. RESULTS: A total of 366 patients were included, of whom 66 (18%) reached an endpoint: 26 (7%) PSC-related death, 40 (11%) liver transplantation. At T0 and T1, 84% used ursodeoxycholic acid. A positive association was observed between level of ALP at T0 and T1 and the hazard of reaching an endpoint, up to values around 2.5 times upper limit of normal (xULN). A larger decrease in ALP between T0 and T1 decreased the event rate. A range of thresholds (0.5-3×ULN) with about similar C-statistics was found. In this cohort, the optimal threshold was 1.3×ULN at T1. CONCLUSION:ALP can be used to discriminate between PSC patients with a good and a poor prognosis. These findings indicate that ALP can serve as stratifier, and potentially as surrogate endpoint for clinical trials in PSC.
Authors: Zeinab Bakhshi; Moira B Hilscher; Gregory J Gores; William S Harmsen; Jason K Viehman; Nicholas F LaRusso; Andrea A Gossard; Konstantinos N Lazaridis; Keith D Lindor; John E Eaton Journal: J Gastroenterol Date: 2020-01-13 Impact factor: 7.527
Authors: John E Eaton; Bryan M McCauley; Elizabeth J Atkinson; Brian D Juran; Erik M Schlicht; Mariza de Andrade; Konstantinos N Lazaridis Journal: J Gastroenterol Hepatol Date: 2017-10 Impact factor: 4.029
Authors: Burcin Özdirik; Martin Maibier; Maria Scherf; Jule Marie Nicklaus; Josephine Frohme; Tobias Puengel; Dirk Meyer Zum Büschenfelde; Frank Tacke; Tobias Mueller; Michael Sigal Journal: J Clin Med Date: 2022-04-28 Impact factor: 4.964
Authors: Amy E Taylor; Alexandra N Carey; Ramesh Kudira; Celine S Lages; Tiffany Shi; Simon Lam; Rebekah Karns; Julia Simmons; Kumar Shanmukhappa; Maha Almanan; Claire A Chougnet; Alexander G Miethke Journal: Hepatology Date: 2018-09-30 Impact factor: 17.425
Authors: John E Eaton; Mette Vesterhus; Bryan M McCauley; Elizabeth J Atkinson; Erik M Schlicht; Brian D Juran; Andrea A Gossard; Nicholas F LaRusso; Gregory J Gores; Tom H Karlsen; Konstantinos N Lazaridis Journal: Hepatology Date: 2018-12-28 Impact factor: 17.425
Authors: Sonja Boyd; Marko Vannas; Kalle Jokelainen; Helena Isoniemi; Heikki Mäkisalo; Martti A Färkkilä; Johanna Arola Journal: World J Gastroenterol Date: 2017-09-07 Impact factor: 5.742